Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Here are 4 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that major milestones (such as clinical trial completions and decisions on regulatory approval) will occur right on cue and that they will be favourable to the…

ByNick SundichFebruary 24, 2026

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

We thought this was a perfect time to ponder the question,' Why share prices fall after a capital raising', in light of what happened with Botanix Pharmaceuticals (ASX:BOT). Its shares fell 33% in less than an hour of trading. Now, shouldn't investors be happy that the company has $45m more cash? Let's just say that…

ByNick SundichFebruary 18, 2026

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

Investors may remember Rhythm Biosciences (ASX:RHY) for its ColoSTAT test, but it is Genetype that is arguably more exciting. The company now has a substantially larger market awaiting us, and while its commercialisation strategy for ColoSTAT has changed, this strategy has been successful. Wait, has Rhythm received TGA approval? Yes and no - it's a long…

ByNick SundichFebruary 17, 2026

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon following a tenure of nearly 3 years. It was clear that something had to give, but this is still a shock as it occurred a day before company results and resulted in McKenzies' tenure lasting…

ByNick SundichFebruary 11, 2026

This company just made an IND submission to the US FDA, here’s why its a big step!

Imagion Biosystems (ASX:IBX) just made a IND submission. This is a big deal for the company, and we thought it would be the perfect time to explain to investors just what this means. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"] [/sg_popup] Here's what you need to know about…

ByNick SundichFebruary 10, 2026

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade. What are the Best ASX Life…

ByNick SundichFebruary 5, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA. The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Here are 4 ASX biotechs with major milestones coming right up!

If you wondered why share prices fall after a capital raising, Botanix is the ‘perfect’ poster child

Rhythm Biosciences (ASX:RHY): Since picking up Genetype, it has never looked back and is more than a one-trick pony!

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

This company just made an IND submission to the US FDA, here’s why its a big step!

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Our 5 ASX Predictions for 2026!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here